BioCentury
ARTICLE | Clinical News

CARsgen reports Phase I data for anti-GPC3 CAR T in HCC

June 9, 2017 7:55 PM UTC

CARsgen Therapeutics Co. Ltd. (Shanghai, China) reported preliminary data from 5 evaluable patients with relapsed or refractory hepatocellular carcinoma (HCC) in a Chinese Phase I trial showing that CSG-GPC3 following lymphodepleting conditioning with fludarabine and cyclophosphamide led to 1 partial response and 2 cases of stable disease. In 13 patients evaluable for safety, CSG-GPC3 was well tolerated with no dose-limiting toxicities (DLTs) or treatment-related serious adverse events reported. Data were presented at the American Society of Clinical Oncology meeting in Chicago. The trial’s primary endpoint is safety...